HIGHLIGHTS
SUMMARY
Studies have reported that the number of CD8-positive T_cells in the tumor is significantly positively correlated with the effectiveness of ICIs therapy. The authors also confirmed the expression of PROZ in sorafenib-resistant strains by in_vitro cell experiments, providing direct evidence that PROZ is related to sorafenib. Anti-VEGF therapy can reverse the immunosuppression of the tumor microenvironment, then directly or indirectly increase the infiltration and proliferation of CD8+ T_cells, thereby significantly enhancing the efficacy of ICIs. The relationship between PROZ and sorafenib resistance was further verified in_vitro, and it was found that . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.